Dyslipidemia refers to abnormalities in lipids and lipoproteins in the circulation and is a key modifiable risk factor for cardiovascular (CV) disease. The most common lipid abnormalities include elevated levels of LDL-cholesterol and/or triglyceride levels. Statins are firmly established as first-line treatment for most patients with dyslipidemia, owing to their proven CV benefits, physician familiarity with the class, and the increased availability of low-priced generic options. However, a lack of high-quality CV outcomes trial data has weakened physicians’ confidence in many nonstatin drug classes, particularly those agents that lower triglyceride levels. Nonetheless, physicians recognize that many statin-treated patients have residual CV risk and consequently use additional therapies, including the efficacious but expensive proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. This report explores the current EU5 prescribing landscape for dyslipidemia and the factors that influence it.

Questions Answered

  • Do physicians have a preference for Praluent or Repatha? What are the major factors driving/constraining use of the PCSK9 inhibitor class?
  • How do drug preferences change at each line of therapy in different geographies?
  • What is influencing the prescribing of endocrinologists and cardiologists for dyslipidemia, and how are these factors expected to change?
  • How do prescribing patterns differ between lipid disorders; which therapies are most popular for the treatment of these different populations?

Product Description

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that clients can create specific messaging around these treatment dynamics in order to more effectively increase or defend their market position.

Geographies:France, Germany, Italy, Spain, and the United Kingdom.

Primary research:128 cardiologists and 128 endocrinologists, with 51 respondents in France, 50 in Germany, 51 in Italy, 53 in Spain, and 51 in the United Kingdom.

Key drugs covered: Repatha (evolocumab), Praluent (alirocumab), statins, fibrates, ezetimibe (Zetia, generics), prescription omega-3 fatty acid compounds.

Table of contents

  • Dyslipidemia - Current Treatment - Detailed, Expanded Analysis: Physician Insights (EU5)
    • Current Treatment: Physician Insights Dyslipidemia (EU5)

Author(s): Andrew Frost

Andrew Frost is a Business Insights Analyst in Decision Resources Group’s Cardiovascular, Metabolic, Renal, and Hematologic Disorders team focusing on obesity and non-alcoholic steatohepatitis (NASH). In this role, he evaluates the latest primary and secondary research, as well as available commercial information, to forecast the potential of developmental drugs and provide insight on the various dynamics affecting relevant markets. Prior to joining DRG, Andrew worked as a Senior Drug Analyst at Citeline in the Cardiovascular and Metabolic Team. Andrew holds a BSc (Hons) degree in Pharmacology, awarded by King’s College London, and he has previously worked in the Immunopharmacology team at UCB.


Related Reports

Dyslipidemia - Landscape & Forecast - Disease Landscape & Forecast

Dyslipidemia is a key modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). Current...

View Details

Dyslipidemia | Disease Landscape and Forecast | G7 | 2020

Dyslipidemia is a key modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). Current lipid-modifying therapies include statins, ezetimibe, fibrates, omega-3 fatty acid compounds...

View Details

Dyslipidemia - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US)

MARKET OUTLOOK Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates, omeg...

View Details

Dyslipidemia - Epidemiology - Mature Markets

DRG Epidemiology’s coverage of dyslipidemia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dyslipidemia for each co...

View Details